Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial

Nam Hoon Kim, Soo Lim, Soo Heon Kwak, Min Kyong Moon, Jun Sung Moon, Yong Ho Lee, Ho Chan Cho, Juneyoung Lee, Sin Gon Kim

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Patients with type 2 diabetes are at risk of microvascular and macrovascular complications. Intensive glycaemic control, especially in patients with short duration of diabetes, is the mainstay of management of type 2 diabetes to lower the risk of complications. However, despite the improvement in the understanding of the pathophysiology of type 2 diabetes and development of novel glucose-lowering agents, long-term durable glycaemic control remains a difficult goal to achieve. Several challenging clinical trials proved that an early combination therapy with a variety of glucose-lowering agents had a more favourable effect than conventional stepwise therapy in terms of glycaemic control. We aim to evaluate the efficacy and tolerability of a novel, initial triple combination therapy with metformin, sodium glucose cotransporter 2 inhibitor (dapagliflozin) and dipeptidyl peptidase-4 inhibitor (saxagliptin) compared with conventional stepwise add-on therapy in drug-naïve patients with recent-onset type 2 diabetes.

METHODS AND ANALYSIS: This study is a multicentre, prospective, randomised, open-label, parallel group, comparator-controlled trial. A total of 104 eligible participants will be randomised to either the initial combination therapy group or the conventional stepwise add-on therapy group for 104 weeks. The primary endpoint is the proportion of patients who achieved haemoglobin A1c level<6.5% without hypoglycaemia, weight gain or discontinuation due to adverse events at 104 weeks. This trial will determine whether a novel triple combination therapy with metformin, dapagliflozin and saxagliptin has a beneficial effect on durable glycaemic control compared with conventional therapy in drug-naïve patients with type 2 diabetes.

ETHICS AND DISSEMINATION: This study protocol was approved by the local institutional review boards and independent ethics committees over the recruitment sites. Results of this study will be disseminated in scientific journals and scientific conferences.

TRIAL REGISTRATION NUMBER: NCT02946632; Pre-results.

Original languageEnglish
Pages (from-to)e022448
JournalBMJ Open
Volume8
Issue number9
DOIs
Publication statusPublished - 2018 Sep 24

Fingerprint

Clinical Protocols
Combination Drug Therapy
Type 2 Diabetes Mellitus
Randomized Controlled Trials
Metformin
Group Psychotherapy
Sodium-Glucose Transport Proteins
Dipeptidyl-Peptidase IV Inhibitors
Glucose
Drug Therapy
Ethics Committees
Research Ethics Committees
Secondary Prevention
Hypoglycemia
Weight Gain
Hemoglobins
Therapeutics
Clinical Trials
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
saxagliptin

Keywords

  • clinical trials
  • therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial : protocol for an open-label randomised controlled trial. / Kim, Nam Hoon; Lim, Soo; Kwak, Soo Heon; Moon, Min Kyong; Moon, Jun Sung; Lee, Yong Ho; Cho, Ho Chan; Lee, Juneyoung; Kim, Sin Gon.

In: BMJ Open, Vol. 8, No. 9, 24.09.2018, p. e022448.

Research output: Contribution to journalArticle

@article{ea53986f9c7b451ea5b66ef962ad1301,
title = "Efficacy and tolerability of novel triple combination therapy in drug-na{\"i}ve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial",
abstract = "INTRODUCTION: Patients with type 2 diabetes are at risk of microvascular and macrovascular complications. Intensive glycaemic control, especially in patients with short duration of diabetes, is the mainstay of management of type 2 diabetes to lower the risk of complications. However, despite the improvement in the understanding of the pathophysiology of type 2 diabetes and development of novel glucose-lowering agents, long-term durable glycaemic control remains a difficult goal to achieve. Several challenging clinical trials proved that an early combination therapy with a variety of glucose-lowering agents had a more favourable effect than conventional stepwise therapy in terms of glycaemic control. We aim to evaluate the efficacy and tolerability of a novel, initial triple combination therapy with metformin, sodium glucose cotransporter 2 inhibitor (dapagliflozin) and dipeptidyl peptidase-4 inhibitor (saxagliptin) compared with conventional stepwise add-on therapy in drug-na{\"i}ve patients with recent-onset type 2 diabetes.METHODS AND ANALYSIS: This study is a multicentre, prospective, randomised, open-label, parallel group, comparator-controlled trial. A total of 104 eligible participants will be randomised to either the initial combination therapy group or the conventional stepwise add-on therapy group for 104 weeks. The primary endpoint is the proportion of patients who achieved haemoglobin A1c level<6.5{\%} without hypoglycaemia, weight gain or discontinuation due to adverse events at 104 weeks. This trial will determine whether a novel triple combination therapy with metformin, dapagliflozin and saxagliptin has a beneficial effect on durable glycaemic control compared with conventional therapy in drug-na{\"i}ve patients with type 2 diabetes.ETHICS AND DISSEMINATION: This study protocol was approved by the local institutional review boards and independent ethics committees over the recruitment sites. Results of this study will be disseminated in scientific journals and scientific conferences.TRIAL REGISTRATION NUMBER: NCT02946632; Pre-results.",
keywords = "clinical trials, therapeutics",
author = "Kim, {Nam Hoon} and Soo Lim and Kwak, {Soo Heon} and Moon, {Min Kyong} and Moon, {Jun Sung} and Lee, {Yong Ho} and Cho, {Ho Chan} and Juneyoung Lee and Kim, {Sin Gon}",
year = "2018",
month = "9",
day = "24",
doi = "10.1136/bmjopen-2018-022448",
language = "English",
volume = "8",
pages = "e022448",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial

T2 - protocol for an open-label randomised controlled trial

AU - Kim, Nam Hoon

AU - Lim, Soo

AU - Kwak, Soo Heon

AU - Moon, Min Kyong

AU - Moon, Jun Sung

AU - Lee, Yong Ho

AU - Cho, Ho Chan

AU - Lee, Juneyoung

AU - Kim, Sin Gon

PY - 2018/9/24

Y1 - 2018/9/24

N2 - INTRODUCTION: Patients with type 2 diabetes are at risk of microvascular and macrovascular complications. Intensive glycaemic control, especially in patients with short duration of diabetes, is the mainstay of management of type 2 diabetes to lower the risk of complications. However, despite the improvement in the understanding of the pathophysiology of type 2 diabetes and development of novel glucose-lowering agents, long-term durable glycaemic control remains a difficult goal to achieve. Several challenging clinical trials proved that an early combination therapy with a variety of glucose-lowering agents had a more favourable effect than conventional stepwise therapy in terms of glycaemic control. We aim to evaluate the efficacy and tolerability of a novel, initial triple combination therapy with metformin, sodium glucose cotransporter 2 inhibitor (dapagliflozin) and dipeptidyl peptidase-4 inhibitor (saxagliptin) compared with conventional stepwise add-on therapy in drug-naïve patients with recent-onset type 2 diabetes.METHODS AND ANALYSIS: This study is a multicentre, prospective, randomised, open-label, parallel group, comparator-controlled trial. A total of 104 eligible participants will be randomised to either the initial combination therapy group or the conventional stepwise add-on therapy group for 104 weeks. The primary endpoint is the proportion of patients who achieved haemoglobin A1c level<6.5% without hypoglycaemia, weight gain or discontinuation due to adverse events at 104 weeks. This trial will determine whether a novel triple combination therapy with metformin, dapagliflozin and saxagliptin has a beneficial effect on durable glycaemic control compared with conventional therapy in drug-naïve patients with type 2 diabetes.ETHICS AND DISSEMINATION: This study protocol was approved by the local institutional review boards and independent ethics committees over the recruitment sites. Results of this study will be disseminated in scientific journals and scientific conferences.TRIAL REGISTRATION NUMBER: NCT02946632; Pre-results.

AB - INTRODUCTION: Patients with type 2 diabetes are at risk of microvascular and macrovascular complications. Intensive glycaemic control, especially in patients with short duration of diabetes, is the mainstay of management of type 2 diabetes to lower the risk of complications. However, despite the improvement in the understanding of the pathophysiology of type 2 diabetes and development of novel glucose-lowering agents, long-term durable glycaemic control remains a difficult goal to achieve. Several challenging clinical trials proved that an early combination therapy with a variety of glucose-lowering agents had a more favourable effect than conventional stepwise therapy in terms of glycaemic control. We aim to evaluate the efficacy and tolerability of a novel, initial triple combination therapy with metformin, sodium glucose cotransporter 2 inhibitor (dapagliflozin) and dipeptidyl peptidase-4 inhibitor (saxagliptin) compared with conventional stepwise add-on therapy in drug-naïve patients with recent-onset type 2 diabetes.METHODS AND ANALYSIS: This study is a multicentre, prospective, randomised, open-label, parallel group, comparator-controlled trial. A total of 104 eligible participants will be randomised to either the initial combination therapy group or the conventional stepwise add-on therapy group for 104 weeks. The primary endpoint is the proportion of patients who achieved haemoglobin A1c level<6.5% without hypoglycaemia, weight gain or discontinuation due to adverse events at 104 weeks. This trial will determine whether a novel triple combination therapy with metformin, dapagliflozin and saxagliptin has a beneficial effect on durable glycaemic control compared with conventional therapy in drug-naïve patients with type 2 diabetes.ETHICS AND DISSEMINATION: This study protocol was approved by the local institutional review boards and independent ethics committees over the recruitment sites. Results of this study will be disseminated in scientific journals and scientific conferences.TRIAL REGISTRATION NUMBER: NCT02946632; Pre-results.

KW - clinical trials

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85054092679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054092679&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2018-022448

DO - 10.1136/bmjopen-2018-022448

M3 - Article

C2 - 30249630

AN - SCOPUS:85054092679

VL - 8

SP - e022448

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 9

ER -